Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapy

Modern Rheumatology

Volumn 25, Issue 6, 2015, Pages 898-902

  Yamamoto, Noboru ^a,b   Sato, Kaoru ^a   Hoshina, Takayuki ^b   Kojiro, Masumi ^a   Kusuhara, Koichi ^b  

^a Kitakyushu General Hospital   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Ferritin; Intravenous immunoglobulin therapy; Refractory Kawasaki disease

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FERRITIN; IMMUNOGLOBULIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASSESSMENT OF HUMANS; CHILD; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FERRITIN BLOOD LEVEL; GUNMA SCORE; HUMAN; IMMUNOTHERAPY; INFANT; KURUME SCORE; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; OSAKA SCORE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SODIUM BLOOD LEVEL; BLOOD; PRESCHOOL CHILD; TREATMENT FAILURE;

BIOMARKERS; CHILD, PRESCHOOL; FEMALE; FERRITINS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE;

EID: 84947038954     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1038430     Document Type: Article

References (26)

1. Burns JC, Glodé MP. Kawasaki syndrome. Lancet. 2004;364(9433):533-44.
2. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-71.
3. Furusho K, Kamiya T, Nakano H, Kiyosawa N, Shinomiya K, Hayashidera T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2(8411):1055-8.
4. Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J. 2008;27(2):155-60.
5. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606-12.
6. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, Matsuishi T. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237-40.
7. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gammaglobulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131-7.
8. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: Past, present and future. Biochim Biophys Acta. 2010;1800(8):760-9.
9. Miller LL, Miller SC, Torti SV, Tsuji Y, Torti FM. Iron-independent induction of ferritin H chain by tumor necrosis factor. Proc Natl Acad Sci USA. 1991;88(11):4946-50.
10. Tsuji Y, Miller LL, Miller SC, Torti SV, Torti FM. Tumor necrosis factor-alpha and interleukin 1-alpha regulate transferrin receptor in human diploid fibroblasts. Relationship to the induction of ferritin heavy chain. J Biol Chem. 1991;266(11):7257-61.
11. Pelkonen P, Swanljung K, Siimes MA. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand. 1986;75(1):64-8.
12. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47(2):232-4.
13. Kim HK, Kim HG, Cho SJ, Hong YM, Sohn S, Yoo ES, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis related to Kawasaki disease. Pediatr Hematol Oncol. 2011;28(3):230-6.
14. Ohga S, Ooshima A, Fukushige J, Ueda K. Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state. Eur J Pediatr. 1995;154(7):539-41.
15. Nasir A, Al Tatari H, Hamdan MA. Very high serum ferritin levels in three newborns with Kawasaki-like illness. Paediatr Child Health. 2012;17(4):201-4.
16. Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn. 1991;41(11):785-97.
17. Takahashi K, Oharaseki T, Yokouchi Y, Naoe S, Saji T. Kawasaki disease: basic and pathological findings. Clin Exp Nephrol. 2013;17(5):690-3.
18. Coffman LG, Parsonage D, D'Agostino R, Jr, Torti FM, Torti SV. Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci USA. 2009;106(2):570-5.
19. Guo L, Jiang F, Tang YT, Si MY, Jiao XY. The association of serum vascular endothelial growth factor and ferritin in diabetic microvascular disease. Diabetes Technol Ther. 2014;16(4):224-34.
20. Ohno T, Yuge T, Kariyazono H, Igarashi H, Joh-o K, Kinugawa N, et al. Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr. 2002;161(2):105-11.
21. Matsuda A, Morita H, Unno H, Saito H, Matsumoto K, Hirao Y, et al. Anti-inflammatory effects of high-dose IgG on TNF-a-activated human coronary artery endothelial cells. Eur J Immunol. 2012;42(8):2121-31.
22. Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831-5.e3.
23. Burns JC, Herzog L, Fabri O, Tremoulet AH, Rodó X, Uehara R, et al. Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013;8(9):e74529.
24. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Eng J Med. 2007;356(7):663-75.
25. Okada K, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, et al. Pulse methylprednisolone with gammagloblin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168(2):181-5.
26. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613-20.